Jundishapur Journal of Microbiology

Published by: Kowsar

Evaluation of Immune Response Against Inactivated Avian Influenza (H9N2) Vaccine, by Using Chitosan Nanoparticles

Iraj Khalili 1 , * , Rahim Ghadimipour 2 , Saeed Sadigh Eteghad 3 , Mohsen Fathi Najafi 4 , Mohammad Majid Ebrahimi 5 , Naser Godsian 6 , Yousef Sefidi Heris 7 and Mohammad Taghi Khalili 8
Authors Information
1 Laboratory of Virus Biobank, Razi Vaccine and Serum Research Institute, Karaj, IR Iran
2 Department of Research and Development, Razi Vaccine and Serum Research Institute, Ahvaz, IR Iran
3 Neurosciences Research Center, Tabriz University of Medical Science, Tabriz, IR Iran
4 Department of Biotechnology, Razi Vaccine and Serum Research Institute, Mashhad, IR Iran
5 Department of Poultry Research and Vaccine Production, Razi Vaccine and Serum Research Institute, Karaj, IR Iran
6 Department of Poultry Vaccines Quality Control, Razi Vaccine and Serum Research Institute, Karaj, IR Iran
7 Higher Education Institute of Rab-Rashidi, Tabriz, IR Iran
8 Department of Poultry Inactivated Vaccines, Razi Vaccine and Serum Research Institute, Marand, IR Iran
Article information
  • Jundishapur Journal of Microbiology: December 01, 2015, 8 (12); e27035
  • Published Online: December 26, 2015
  • Article Type: Research Article
  • Received: February 6, 2015
  • Revised: March 18, 2015
  • Accepted: April 13, 2015
  • DOI: 10.5812/jjm.27035

To Cite: Khalili I, Ghadimipour R, Sadigh Eteghad S, Fathi Najafi M, Ebrahimi M M, et al. Evaluation of Immune Response Against Inactivated Avian Influenza (H9N2) Vaccine, by Using Chitosan Nanoparticles, Jundishapur J Microbiol. 2015 ; 8(12):e27035. doi: 10.5812/jjm.27035.

Abstract
Copyright © 2015, Ahvaz Jundishapur University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Capua I, Alexander DJ. Avian influenza and Newcastle disease: a field and laboratory manual. 2009; : 1-18[DOI]
  • 2. Hem SL. Elimination of aluminum adjuvants. Vaccine. 2002; 20 Suppl 3-3[PubMed]
  • 3. Illum L. Chitosan and its use as a pharmaceutical excipient. Pharm Res. 1998; 15(9): 1326-31[PubMed]
  • 4. Leenaars PP, Hendriksen CF, Koedam MA, Claassen I, Claassen E. Comparison of adjuvants for immune potentiating properties and side effects in mice. Vet Immunol Immunopathol. 1995; 48(1-2): 123-38[PubMed]
  • 5. Hinshaw VS, Webster RG, Easterday BC, Bean WJ. Replication of avian influenza: A viruses in mammals. Infect Immun. 1981; 34(2): 354-61[PubMed]
  • 6. Burleson FG, Chambers TM, Wiedbrauk DL. A laboratory manual London, Virology 1992; : 66-72[DOI]
  • 7. Shu XZ, Zhu KJ. Chitosan/gelatin microspheres prepared by modified emulsification and ionotropic gelation. J Microencapsul. 2001; 18(2): 237-45[DOI][PubMed]
  • 8. Sinha VR, Singla AK, Wadhawan S, Kaushik R, Kumria R, Bansal K, et al. Chitosan microspheres as a potential carrier for drugs. Int J Pharm. 2004; 274(1-2): 1-33[DOI][PubMed]
  • 9. Singh M. Vaccine adjuvants and delivery systems. 2007; : 1-157
  • 10. Yamanaka M, Okabe T, Kodama K, Goto N. Local pathological reactions induced in pigs and cats by adjuvant ISA-70 containing inactivated newcastle disease virus antigen. J Vet Med Sci. 1994; 56(1): 185-7[PubMed]
  • 11. Stills HF. Adjuvants and antibody production: dispelling the myths associated with Freund's complete and other adjuvants. ILAR J. 2005; 46(3): 280-93[PubMed]
  • 12. Keitel WA, Dekker CL, Mink C, Campbell JD, Edwards KM, Patel SM, et al. Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults. Vaccine. 2009; 27(47): 6642-8[DOI][PubMed]
  • 13. Bacon A, Makin J, Sizer PJ, Jabbal-Gill I, Hinchcliffe M, Illum L, et al. Carbohydrate biopolymers enhance antibody responses to mucosally delivered vaccine antigens. Infect Immun. 2000; 68(10): 5764-70[PubMed]
  • 14. Ghendon Y, Markushin S, Krivtsov G, Akopova I. Chitosan as an adjuvant for parenterally administered inactivated influenza vaccines. Arch Virol. 2008; 153(5): 831-7[DOI][PubMed]
  • 15. Ghendon Y, Markushin S, Vasiliev Y, Akopova I, Koptiaeva I, Krivtsov G, et al. Evaluation of properties of chitosan as an adjuvant for inactivated influenza vaccines administered parenterally. J Med Virol. 2009; 81(3): 494-506[DOI][PubMed]
  • 16. O'Hagan DT, Singh M. Microparticles as vaccine adjuvants and delivery systems. Expert Rev Vaccines. 2003; 2(2): 269-83[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments